Walgreens reaches $230 mln opioid settlement with San Francisco
Adds previous Walgreens settlement with Florida in paragraph 12, closing stock price in paragraph 15
By Jonathan Stempel
May 17 (Reuters) -San Francisco said on Wednesday it reached a $230 million settlement with Walgreens Boots Alliance Inc WBA.O over its role in the city's opioid epidemic.
The settlement came nine months after U.S. District Judge Charles Breyer in San Francisco said the drugstore chain could be held liable for having "substantially contributed" to an opioid epidemic that caused "widespread harm" in the city and constituted a public nuisance.
Breyer faulted Walgreens for its "15-year failure" to properly scrutinize opioid prescriptions and flag possible misuse of the sometimes highly addictive drugs.
At a press conference, San Francisco City Attorney David Chiu called Walgreens' settlement the largest awarded to a local government in years of opioid litigation nationwide.
He said Walgreens' actions "made the opioid epidemic in San Francisco worse than it otherwise would have been," and that there is "no amount of money that will bring back the lives we have lost."
In a statement, Walgreens said it "disputes liability" and did not admit fault, but that settling allows it to focus on patients, customers and communities. "Our thoughts are with those impacted by this tragic crisis," it added.
The Deerfield, Illinois-based company had been the only remaining defendant in San Francisco's civil lawsuit, after several drugmakers and distributors reached settlements worth more than $120 million.
In his ruling last Aug. 10, following a non-jury trial, Breyer found that Walgreens suffered from a profit-driven "fill, fill, fill" culture in dispensing opioids.
Breyer found that Walgreens' San Francisco pharmacies had received more than 1.2 million opioid prescriptions with "red flags" from 2006 to 2020, yet performed due diligence on less than 5% before dispensing them.
Walgreens' settlement averts a trial to determine damages.
San Francisco had estimated it might cost $8.1 billion to abate the opioid crisis, and that Walgreens was legally liable for the entire amount.
Last May, Walgreens reached a $683 million opioid settlement with Florida, paying more than three-quarters of the $878 million that four other companies, including rival CVS Health Corp CVS.N, agreed to pay in similar, earlier settlements.
Opioids include legal painkillers such as OxyContin, and various forms of the drug fentanyl.
More than 600,000 people have died from drug overdoses in the United States from 1999 to 2021, including more than 107,000 in 2021 alone, according to the U.S. Centers for Disease Control and Prevention.
Walgreens shares closed up 69 cents at $32.04 in Wednesday trading on Nasdaq.
Reporting by Jonathan Stempel in New York; Additional reporting by Dietrich Knauth; Editing by Aurora Ellis and Sonali Paul
Activos relacionados
Últimas noticias
Descargo de responsabilidades: Cada una de las entidades de XM Group proporciona un servicio de solo ejecución y acceso a nuestra plataforma de trading online, permitiendo a una persona ver o usar el contenido disponible en o a través del sitio web, sin intención de cambiarlo ni ampliarlo. Dicho acceso y uso están sujetos en todo momento a: (i) Términos y Condiciones; (ii) Advertencias de riesgo; y (iii) Descargo completo de responsabilidades. Por lo tanto, dicho contenido se proporciona exclusivamente como información general. En particular, por favor tenga en cuenta que, los contenidos de nuestra plataforma de trading online no son ni solicitud ni una oferta para entrar a realizar transacciones en los mercados financieros. Operar en cualquier mercado financiero implica un nivel de riesgo significativo para su capital.
Todo el material publicado en nuestra plataforma de trading online tiene únicamente fines educativos/informativos y no contiene –y no debe considerarse que contenga– asesoramiento ni recomendaciones financieras, tributarias o de inversión, ni un registro de nuestros precios de trading, ni una oferta ni solicitud de transacción con instrumentos financieros ni promociones financieras no solicitadas.
Cualquier contenido de terceros, así como el contenido preparado por XM, como por ejemplo opiniones, noticias, investigaciones, análisis, precios, otras informaciones o enlaces a sitios de terceros que figuran en este sitio web se proporcionan “tal cual”, como comentarios generales del mercado y no constituyen un asesoramiento en materia de inversión. En la medida en que cualquier contenido se interprete como investigación de inversión, usted debe tener en cuenta y aceptar que dicho contenido no fue concebido ni elaborado de acuerdo con los requisitos legales diseñados para promover la independencia en materia de investigación de inversiones y, por tanto, se considera como una comunicación comercial en virtud de las leyes y regulaciones pertinentes. Por favor, asegúrese de haber leído y comprendido nuestro Aviso sobre investigación de inversión no independiente y advertencia de riesgo en relación con la información anterior, al que se puede acceder aquí.
